Paris-based AB Science has announced the pan-European launch of its veterinary anti-cancer drug for the treatment of dogs with non-resectable grade 2 or 3 mast cell tumours.
Masivet was approved in November 2008 by the European Medicines Agency (EMEA).
Unlike chemotherapies, Masivet is delivered orally in tablet form andcan be administered everyday directly by the owner, albeit under strictmonitoring from the veterinarian. Masivet is available on prescriptionat two doses (50 or 150mg) in bottles of 30 tablets.
Masivet’s active pharmaceutical ingredient is masitinib, a tyrosine kinase inhibitor that was discovered and developed by AB Science. Mastinib belongs to a therapeutic class of drug known as “targeted therapy” that is said to be revolutionising the treatment of cancer in humans.
Alain Moussy, CEO of AB Science said: “Masivet is the first product ever registered as a cancer treatment in veterinary medicine. AB Science is proud to have introduced a drug that can extend the life of dogs suffering from cancer ahead of the large pharmaceutical companies.”
Malcolm Brearley, principal clinical oncologist at The Queen’s Veterinary School Hospital at the University of Cambridge, said: “The launch of Masivet is a major breakthrough in cancer and paves the wayfor an exciting period of new development of targeted therapies, usedalone or in combination with standard chemotherapy.
“Masivet is able notonly to increase the survival of dogs with cancer but also to improvetheir quality of life, which is after all the ultimate goal of anytreatment against cancer and offers tremendous value for the pet’sowner.”
For further details, visit www.masivet.com
Masivet demonstrated efficacy and safety with a placebo controlledstudy involving 202 dogs in Europe and the USA. The median survivaltime of dogs treated with Masivet was increased by 300 days incomparison to the placebo. After two years of treatment, the survivalrate in dogs treated with Masivet was 2.5 times that of the dogsreceiving the placebo (40 per cent versus 15 per cent). Efficacy was also demonstratedin the ability of Masivet to prevent the progression of the tumours (anaverage gain of 100 days).